ATE418548T1 - Substituierte 3-cyanothiophen acetamide als glucagon receptor antagonisten - Google Patents

Substituierte 3-cyanothiophen acetamide als glucagon receptor antagonisten

Info

Publication number
ATE418548T1
ATE418548T1 AT04726965T AT04726965T ATE418548T1 AT E418548 T1 ATE418548 T1 AT E418548T1 AT 04726965 T AT04726965 T AT 04726965T AT 04726965 T AT04726965 T AT 04726965T AT E418548 T1 ATE418548 T1 AT E418548T1
Authority
AT
Austria
Prior art keywords
glucagon receptor
cyanothiophene
acetamide
substituted
receptor antagonists
Prior art date
Application number
AT04726965T
Other languages
English (en)
Inventor
Shawn ERICKSON
Paul Gillespie
Kevin Guertin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE418548T1 publication Critical patent/ATE418548T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT04726965T 2003-04-16 2004-04-13 Substituierte 3-cyanothiophen acetamide als glucagon receptor antagonisten ATE418548T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46320003P 2003-04-16 2003-04-16

Publications (1)

Publication Number Publication Date
ATE418548T1 true ATE418548T1 (de) 2009-01-15

Family

ID=33300050

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04726965T ATE418548T1 (de) 2003-04-16 2004-04-13 Substituierte 3-cyanothiophen acetamide als glucagon receptor antagonisten

Country Status (15)

Country Link
US (1) US7138529B2 (de)
EP (1) EP1620425B1 (de)
JP (1) JP4599347B2 (de)
KR (1) KR100779324B1 (de)
CN (1) CN100398533C (de)
AT (1) ATE418548T1 (de)
AU (1) AU2004230220B2 (de)
BR (1) BRPI0409454A (de)
CA (1) CA2521732C (de)
DE (1) DE602004018630D1 (de)
ES (1) ES2316978T3 (de)
MX (1) MXPA05010998A (de)
PL (1) PL1620425T3 (de)
RU (1) RU2336274C2 (de)
WO (1) WO2004092156A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2818547B1 (fr) * 2000-12-22 2006-11-17 Oreal Nouveaux derives c-glycosides et utilisation
AU2003270390A1 (en) * 2002-09-12 2004-04-30 Merck & Co., Inc. Substituted bicyclic thiophene derivatives, compositions containing such compounds and methods of use
US20050085531A1 (en) * 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
PL1753512T3 (pl) * 2004-05-28 2009-03-31 4Sc Ag Tetrahydropirydotiofeny
CA2568718A1 (en) * 2004-06-04 2005-12-15 Altana Pharma Ag Tetrahydropyridothiophenes for use in the treatment of cancer
US20090209534A1 (en) * 2004-06-11 2009-08-20 Klaus Pekari Novel compounds and use of tetrahydropyridopyridothiophenes
WO2005120642A2 (en) * 2004-06-11 2005-12-22 Altana Pharma Ag Tetrahydropyridothiophenes for treating hyperproliferative disorders
DE102004051188A1 (de) * 2004-10-21 2006-04-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Cyanothiophene, deren Herstellung und deren Verwendung als Arzneimittel
EP1851229A1 (de) * 2005-02-09 2007-11-07 Nycomed GmbH Tetrahydropyridothiophene zur behandlung von proliferativen krankheiten wie krebs
US20090252706A1 (en) * 2005-02-11 2009-10-08 Klaus Pekari Tetrahydropyridothiophenes As Antripoliferative Agents For The Treatment Of Cancer
WO2006084904A1 (en) * 2005-02-11 2006-08-17 Nycomed Gmbh Tetrahydropyridothiophenes as antripoliferative agents for the treatment of cancer
JP2008542243A (ja) * 2005-05-25 2008-11-27 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規のテトラヒドロピリドチオフェン
JP2008542242A (ja) * 2005-05-25 2008-11-27 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規のテトラヒドロピリドチオフェン
PT2129654E (pt) 2007-02-09 2014-09-04 Metabasis Therapeutics Inc Antagonistas do receptor de glucagina
FR2921367B1 (fr) * 2007-09-26 2009-10-30 Servier Lab Nouveau procede de synthese du ranelate de strontium et de ses hydrates
MX2011001708A (es) 2008-08-13 2011-04-26 Metabasis Therapeutics Inc Antagonistas de glucagon.
WO2012085745A1 (en) 2010-12-23 2012-06-28 Pfizer Inc. Glucagon receptor modulators
PT2673260T (pt) 2011-02-08 2016-10-24 Pfizer Modulador do recetor de glucagon
JP5647379B2 (ja) 2011-07-22 2014-12-24 ファイザー・インク キノリニルグルカゴン受容体モジュレーター
JP2017519000A (ja) 2014-06-12 2017-07-13 リガンド・ファーマシューティカルズ・インコーポレイテッド グルカゴンアンタゴニスト
CN111978319B (zh) 2014-06-27 2023-08-11 诺格拉制药有限公司 芳基受体调制剂及其制备和使用方法
JP2021513564A (ja) 2018-02-13 2021-05-27 リガンド・ファーマシューティカルズ・インコーポレイテッド グルカゴン受容体拮抗薬
EP4169925B1 (de) * 2018-06-19 2025-11-19 Novartis AG Verfahren zur herstellung von n-substituierte tetrahydrothienopyridinderivate und ihre verwendungen
CN114957278B (zh) * 2021-02-20 2023-08-11 兰州大学 胰高血糖素受体拮抗剂及其用途
CN117343011A (zh) * 2023-09-28 2024-01-05 晨伫(杭州)生物科技有限责任公司 基于吡唑基-磺酰基-苯基骨架结构的化合物及其制备方法和应用、药物组合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206375A (en) * 1985-03-02 1993-04-27 Basf Aktiengesellschaft Thiophene derivatives
DE4236400A1 (de) * 1992-10-28 1994-05-05 Bayer Ag N-Phenylacetaminonitrile
US5981567A (en) * 1993-07-02 1999-11-09 Bayer Aktiengesellschaft Substituted spiroheterocyclic 1h-3-aryl-pyrrolidine-2,4-dione derivatives and their use as pesticides
AU6290998A (en) 1997-03-07 1998-09-29 Novo Nordisk A/S 4,5,6,7-tetrahydro-thieno{3,2-c}pyridine derivatives, their preparation and use
US6262044B1 (en) * 1998-03-12 2001-07-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPASES)
WO1999046267A1 (en) 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
AU5154699A (en) 1998-09-02 2000-03-27 Novo Nordisk A/S 4,5,6,7-tetrahydro-thieno(2,3-c)pyridine derivatives
US20020045613A1 (en) * 2000-04-27 2002-04-18 Heinz Pauls 1-aroyl-piperidinyl benzamidines
GB0114185D0 (en) * 2001-06-12 2001-08-01 Protherics Molecular Design Lt Compounds
US6919365B2 (en) * 2001-04-11 2005-07-19 Senju Pharmaceutical Co., Ltd. Imidazolidinedione derivatives and use thereof as drugs
WO2002085909A1 (en) * 2001-04-20 2002-10-31 Vertex Pharmaceuticals Incorporated 9-deazaguanine derivatives as inhibitors of gsk-3
CA2498399A1 (en) 2002-09-12 2004-03-25 Merck & Co., Inc. Method of treating diabetes and related conditions
AU2003270390A1 (en) 2002-09-12 2004-04-30 Merck & Co., Inc. Substituted bicyclic thiophene derivatives, compositions containing such compounds and methods of use
US7196106B2 (en) * 2002-11-05 2007-03-27 Merck & Co., Inc Cyanothiophene derivatives, compositions containing such compounds and methods of use

Also Published As

Publication number Publication date
JP4599347B2 (ja) 2010-12-15
EP1620425A1 (de) 2006-02-01
KR100779324B1 (ko) 2007-11-28
AU2004230220A1 (en) 2004-10-28
PL1620425T3 (pl) 2009-06-30
MXPA05010998A (es) 2005-12-12
CN100398533C (zh) 2008-07-02
CA2521732A1 (en) 2004-10-28
EP1620425B1 (de) 2008-12-24
RU2336274C2 (ru) 2008-10-20
RU2005135338A (ru) 2007-05-27
CN1774433A (zh) 2006-05-17
BRPI0409454A (pt) 2006-05-02
KR20060011959A (ko) 2006-02-06
AU2004230220B2 (en) 2009-09-17
ES2316978T3 (es) 2009-04-16
WO2004092156A1 (en) 2004-10-28
DE602004018630D1 (en) 2009-02-05
JP2006523641A (ja) 2006-10-19
US20040209943A1 (en) 2004-10-21
CA2521732C (en) 2011-06-07
US7138529B2 (en) 2006-11-21

Similar Documents

Publication Publication Date Title
ATE418548T1 (de) Substituierte 3-cyanothiophen acetamide als glucagon receptor antagonisten
ATE482210T1 (de) Oxadiazolderivate als s1p1-rezeptor-agonisten
ATE384050T1 (de) Benzazepinderivate als histamin-h3-antagonisten
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
EA200870460A1 (ru) Производные циклогексилпиразол-лактама в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы 1
DE602007007614D1 (de) Substituierte pyrrolidinone als hemmer von 11-beta-hydroxysteroiddehydrogenase 1
ECSP066886A (es) Compuestos y métodos para el tratamiento de dislipidemia
BRPI0715893A2 (pt) composto de azetidina e uso para a preparaÇço de um medicamento para a prevenÇço ou tratamento de distérbios distÍmicos ou do sono
MY148429A (en) Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
IS8503A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
DE602004027021D1 (de) Cgrp-rezeptorantagonisten
ATE475645T1 (de) Pyrrolidinderivate als doppelte nk1/nk3- rezeptorenantagonisten
ATE446962T1 (de) Thiazolopyridinon-derivate als mch- rezeptorantagonisten
ATE384058T1 (de) Thiazolderivate
ATE484505T1 (de) 5-sulfanylmethylä1,2,4ütriazolä1,5-aüpyrimidin- - olderivate als cxcr2-antagonisten
MX2009005358A (es) Derivados de 5-sulfanilmetil-pirazolo[1,5-a]pirimidin-7-ol como antagonistas de cxcr2.
EA200501595A1 (ru) Азабициклические производные в качестве антагонистов мускаринового рецептора
DE602005023197D1 (de) -muscarinrezeptors
DE602005027230D1 (de) Cgrp-rezeptorantagonisten
DK1828177T3 (da) Hidtil ukendte MCH-receptorantagonister
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
ATE478856T1 (de) Spirobenzodioxole und deren verwendung als cb1- antagonisten
AR056321A1 (es) COMBINACIONES TERAPÉUTICAS PARA EL TRATAMIENTO O LA PREVENCIoN DE TRASTORNOS PSICoTICOS
ATE466842T1 (de) 3-substituierte pyridinderivate als h3- antagonisten
DK1673354T3 (da) Arylindenopyridiner og arylindenopyrimidiner og deres anvendelse som adenosin-A2a-receptorantagonister

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1620425

Country of ref document: EP